Please try another search
Symbol | Exchange | Currency | ||
---|---|---|---|---|
PHO | Oslo | NOK | Real-time | |
0IMT | London | NOK | Real-time | |
PHONOK | Stockholm | NOK | Real-time |
Photocure ASA is a Norway-based company active in the pharmaceutical industry. The Company is focused on developing and improving photodynamic technology and owns a Photocure Technology platform, which develops photodynamic technology for diagnosis and therapy. Based on the Photocure Technology platform, Photocure has developed and commercialized Hexvix (Hyperthermic IntraVEsical Chemotherapy) and Cysview (hexaminolevulinate HCL) for use in bladder cancer. The Company’s activities are divided into two business segments: The Commercial Franchise and The Development Portfolio. The Commercial Franchise segment includes Hexvix/Cysview by geography (U.S. and Europe) and other sales (partners and other products including sales revenues for Hivec). The Development Portfolio segment includes development of pipeline products.
Name | Age | Since | Title |
---|---|---|---|
Anne Worsøe | - | - | Director |
Johanna Holldack | - | 2017 | Independent Director |
Neal D. Shore | - | - | Director |
Dylan Hallerberg | - | 2023 | Interim Chairman |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review